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Thalassaemia is an inherited blood disorder in which there is a reduction or 
absence in the synthesis of the globin chains of human Hb. Thalassaemia 
remains a public health problem in Malaysia, with many not knowing they 
carry the gene for thalassaemia. Individuals may be carriers of both a and P- 
thalassaemia. Concurrent a-thalassaemia 1 ( (~a / - -~~*)  and (3-thalassaemia 
(PA/PO) carriers are potential parents to offspring with Hb Bart's hydrops 
foetalis (--SEA/--SEA) and Fthalassaemia major (PO/PO). Hb Bart's hydrops 
foetalis results from homozygous state of a-thalassaemia 1 and P- 
thalassaemia major from homozygous Po. 
This study determines the frequency of concurrent carriers of alpha and beta- 
thalassaemia. The information gathered from this study will aid government 
agencies in policy-making, specifically on whether concurrent a- 
thalassaemia 1 identification needs to be done in any national screening 
programme for thalassaemia. Currently, most national screening 
programmes for thalassaemia including that in Malaysia concentrates on P- 
thalassaemia. 
Blood samples were analyzed using conventional haematological methods. 
These include full blood counts/red cell indices followed by Hb analysis to 
quantify Hb subtypes by high performance liquid chromatography (HPLC). 
A thalassaemia carrier is presumptively identified by a cut-off value of 
MCV40fL and MCHc27pg. On HPLC, those with HbA2>4.0% are identified 
as P-thalassaemia carriers. DNA was extracted from blood samples of the P- 
thalassaemia carriers and Gap-polymerase chain reaction (Gap-PCR) was 
done to identify the a-thalassaemia 1 molecular defect. The amplified 
product was run on 1.5% agarose gel by electrophoresis. The separated PCR 
product was then viewed under UV transillumination to identify the 
characteristic 570bp band for the a-thalassaemia 1 determinant. 
A total of 231 P-thalassaemia samples were studied. Eight were found to 
have concurrently inherited the a-thalassaemia 1 (-SEA) deletion, representing 
a carrier rate of 3.5%. The high carrier rate for a-thalassaemia 1 indicates the 
need for the implementation of DNA analysis to complement thalassaemia 
diagnosis in a population screening programme. The relative risk of Chinese 
Malaysian to a non-Chinese being a concurrent carrier of a-thalassaemia 1 
(--SEA) and P-thalassaemia is 2.8 fold. 
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Thalassaemia ialah sejenis penyakit darah keturunan di mana sintesis rantai 
globin dalam hemoglobin manusia berkurangan atau langsung tidak hadir. 
Thalassaemia kekal sebagai masalah kesihatan awam di Malaysia, dengan 
ramai yang tidak tahu mereka sebenarnya pembawa gen thalassaemia. 
Seseorang individu boleh membawa kedua-dua gene a and P-thalassaemia. 
Pembawa serentak a-thalassaemia 1 dan P-thalassaemia (PA/(SD) 
berpotensi untuk melahirkan anak yang mempunyai penyakit Hb Bart's 
hydrops foetalis (--SEA/--SEA) dan kthalassaemia major (fP/m. Hb Bart's 
hydrops foetalis disebabkan oleh keadaan homozygous a-thalassaemia 1 dan 
kthalassaemia major oleh keadaan homozygous f3O. 
Kajian ini menentukan kadar pambawa serentak alpha dan beta- 
thalassaemia. Maklumat ini akan diberi kepada agensi kerajaan untuk 
menentukan sama ada identifikasi serentak a-thalassaemia 1 perlu 
dijalankan dalam program penyaringan awam tha!assaemia. Buat masa ini, 
kebanyakan program penyaringan awam thalassaemia tertumpu pada P- 
thalassaemia. termasuklah yang dijalankan di Malaysia. 
Sampel darah dianalisa dengan menggunakan kaedah hematologi 
konvensional, termasuklah pengiraan darah automasi/indices sel darah 
merah, diikuti dengan analisa hemoglobin oleh 'high performance liquid 
chromatography' (HPLC) untuk mengkuantifikasikan hemoglobin mengikut 
jenis. Pada mulanya, golongan yang mempunyai MCV<BOfL dan MCHc27pg 
dianggap sebagai pembawa thalassaemia. Dengan HPLC, sampel yang 
mempunyai HbA2>4.0% dikenali sebagai pembawa P-thalassaemia. DNA 
diekstrak dari sampel darah pembawa P-thalassaemia dan seterusnya 'Gap- 
polymerase chain reaction' (Gap-PCR) dijalankan untuk mengenalpasti 
kewujudan mutasi a-thalassaemia 1. Produk amplifikasi dianalisa atas gel 
agaros 1.5% dengan elektroforesis. Produk PCR yang dipisahkan dilihat 
dengan, menggunakan cahaya UV untuk mengenalpasti saiz 570bp a- 
thalassaemia 1. 
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Sejumlah 231 sampel P-thalassaemia dikaji. Lapan dikenalpasti sebagai 
pambawa serentak yang mempunyai mutasi (--SEA) a-thalassaemia I. Ini 
mewakili kadar pembawa sebagai 3.5%. Kadar pembawa yang tinggi bagi a- 
thalassaemia 1 menunjukkan perlunya implimentasi analisa DNA bagi 
mengkomplementasikan diagnosis thalassaemia dalam program 
penyaringan awam. Peluang relatif seorang rakyat Malaysia berbangsa Cina 
dikenalpasti sebagai pembawa serentak a-thalassaemia 1 (--SEA) dan P- 
thalassaemia berbanding dengan seorang rakyat Malaysia bukan Cina ialah 
. . . 
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CHAPTER 1 
INTRODUCTION AND OBJECTIVES 
1.1 Introduction 
Thalassaemia is a disorder of haemoglobin (Hb) synthesis 
characterized by the absence or reduced synthesis of one or more of the 
globin chains, a, P, y, 6, E and 5 of human Hb. The two main types of 
thalassaemia that are clinically important are a and 6-thalassaemia 
(Weatherall and Clegg, 2001). 
Alpha-thalassaemia is the most common haemoglobin disorder in the 
world. Deletions of either one (a-thalassaemia 2) or both (a-thalassaemia I) 
a-globin genes on chromosome 16 account for over 95% of a-thalassaemia 
cases (Higgs et al., 1989). 
In Southeast Asia, the form of mutation in a-thalassaemia 1 carriers is 
most commonly the SEA deletion (--SEA). Alpha-thalassaemia 1 (-SEA) 
carriers are at risk of having Hb Bart's hydrops foetalis offspring that 
usually dies in utero at the third trimester of pregnancy or shortly after birth 
